ELIQUIS

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug ELIQUIS contains one active pharmaceutical ingredient (API):

1	Apixaban UNII 3Z9Y7UWC1J - APIXABAN
	Apixaban is a potent, oral, reversible, direct and highly selective active site inhibitor of factor Xa. It does not require antithrombin III for antithrombotic activity. Apixaban inhibits free and clot-bound factor Xa, and prothrombinase activity. By inhibiting factor Xa, apixaban prevents thrombin generation and thrombus development.
	Read more about Apixaban

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ELIQUIS Granules in capsules for opening	MPI, EU: SmPC	European Medicines Agency (EU)
ELIQUIS Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B01AF02		B Blood and blood forming organs → B01 Antithrombotic agents → B01A Antithrombotic agents → B01AF Direct factor Xa inhibitors
Discover more medicines within B01AF02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10414D, 2735Y, 2744K, 5054B, 5061J, 5500L
BR	Câmara de Regulação do Mercado de Medicamentos	522720030084817, 522720030084917, 522720030085017, 522720030085117, 552817120062917
CA	Health Products and Food Branch	02377233, 02397714
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	H4840513, H4850513
EE	Ravimiamet	1531426, 1531437, 1531448, 1603729, 1603730, 1603741, 1603752, 1603763, 1603774, 1603785, 1603796, 1603808, 1658066, 1658088, 1790366
ES	Centro de información online de medicamentos de la AEMPS	111691009, 111691010, 111691014, 11691002, 11691003, 11691005
FI	Lääkealan turvallisuus- ja kehittämiskeskus	071521, 186376, 375471, 426359, 445310
FR	Base de données publique des médicaments	61902218, 69340279
GB	Medicines & Healthcare Products Regulatory Agency	195070, 195072, 195073, 216776, 296794, 367652, 367654, 374352, 374353, 374355, 374356, 379805, 379807, 381321, 381323, 381324
HK	Department of Health Drug Office	61377, 62094
IE	Health Products Regulatory Authority	14024, 14025, 14047, 31468, 31469, 36807, 36814, 36834
IL	מִשְׂרַד הַבְּרִיאוּת	6941, 7157
JP	医薬品医療機器総合機構	3339004F1029, 3339004F2025
LT	Valstybinė vaistų kontrolės tarnyba	1060678, 1060679, 1060680, 1060681, 1060682, 1068553, 1068554, 1068555, 1068556, 1068557, 1068558, 1068559, 1068560, 1074840, 1074841
NL	Z-Index G-Standaard, PRK	105678, 99066
NZ	Medicines and Medical Devices Safety Authority	15592, 15593
PL	Rejestru Produktów Leczniczych	100245589, 100288512
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W65619003, W65620009
SG	Health Sciences Authority	14279P, 14407P
TN	Direction de la Pharmacie et du Médicament	15383011, 15383012, 1673041, 1673042, 1673043
TR	İlaç ve Tıbbi Cihaz Kurumu	8681308010087, 8681308010094, 8681308095152, 8681308096166, 8681308098016, 8681308098023
US	FDA, National Drug Code	0003-0893, 0003-0894, 55154-0612, 55154-0613, 63629-7747, 67296-1673, 70518-1861
ZA	Health Products Regulatory Authority	47/8.2/0464